Mangalam Drugs and Organics Ltd Stock Price Today (NSE: MANGALAM)
Fundamental Score
Mangalam Drugs and Organics Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Mangalam Drugs and Organics Ltd share price today is ₹26.98, down 0.33% on NSE/BSE as of 3 August 2026. Mangalam Drugs and Organics Ltd (MANGALAM) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of ₹43.97 (Cr). The 52-week high for MANGALAM share price is ₹90.85 and the 52-week low is ₹22.80. The company has a Return on Equity (ROE) of -34.77% and a debt-to-equity ratio of 1.02.
Mangalam Drugs and Organics Ltd Share Price Chart — NSE/BSE Historical Performance
Mangalam Drugs and Organics Ltd share price chart: -4.68% return over the past month. 52-week high ₹90.85, 52-week low ₹22.80.
Mangalam Drugs and Organics Ltd — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹27.07 | ₹27.49 | ₹26.33 | ₹27.11 | 8.75K (Cr) | |
| ₹27.73 | ₹27.73 | ₹26.90 | ₹27.07 | 24.20K (Cr) | |
| ₹27.50 | ₹27.77 | ₹26.70 | ₹27.14 | 25.64K (Cr) | |
| ₹27.80 | ₹27.80 | ₹26.41 | ₹27.46 | 18.80K (Cr) | |
| ₹27.22 | ₹27.79 | ₹27.07 | ₹27.42 | 8.63K (Cr) | |
| ₹27.17 | ₹27.67 | ₹26.40 | ₹27.22 | 12.09K (Cr) | |
| ₹27.29 | ₹27.81 | ₹27.02 | ₹27.26 | 16.83K (Cr) | |
| ₹27.99 | ₹27.99 | ₹27.01 | ₹27.29 | 10.05K (Cr) | |
| ₹27.88 | ₹27.92 | ₹27.06 | ₹27.59 | 11.32K (Cr) | |
| ₹27.50 | ₹28.68 | ₹27.15 | ₹27.39 | 25.18K (Cr) |
Mangalam Drugs and Organics Ltd — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹28.14 | ₹29.30 | ₹26.33 | ₹27.11 | -3.66% | |
| ₹29.50 | ₹31.05 | ₹27.00 | ₹28.14 | -4.61% | |
| ₹29.48 | ₹31.49 | ₹28.01 | ₹28.76 | -2.44% | |
| ₹26.51 | ₹33.05 | ₹26.51 | ₹29.48 | +11.20% | |
| ₹27.63 | ₹35.40 | ₹26.54 | ₹27.15 | -1.74% | |
| ₹32.68 | ₹37.90 | ₹28.46 | ₹29.08 | -11.02% | |
| ₹28.88 | ₹54.40 | ₹28.88 | ₹36.20 | +25.35% | |
| ₹26.53 | ₹29.32 | ₹22.80 | ₹27.51 | +3.69% | |
| ₹65.40 | ₹67.19 | ₹27.93 | ₹27.93 | -57.29% | |
| ₹72.30 | ₹73.90 | ₹62.75 | ₹65.40 | -9.54% | |
| ₹75.39 | ₹79.70 | ₹70.50 | ₹71.63 | -4.99% | |
| ₹89.82 | ₹90.85 | ₹72.60 | ₹74.30 | -17.28% |
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Mangalam Drugs and Organics Ltd Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Mangalam Drugs and Organics Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of MANGALAM across key market metrics for learning purposes.
Positive Indicators
1 factors identified
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
9 factors identified
Below-Average Return on Equity (-34.77%)
Observation: Returns on equity are below industry benchmarks.
Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.
Suboptimal ROCE (-14.01%)
Observation: Returns on capital employed are below expectations.
Analysis: ROCE <10% suggests potential inefficiencies in capital allocation.
Profit Decline Concern (-8806.67%)
Observation: Significant year-over-year profit contraction observed.
Analysis: Declining profitability requires investigation into underlying causes.
Revenue Contraction (-7.54%)
Observation: Sales decline may indicate market challenges or competitive pressures.
Analysis: Negative revenue growth requires analysis of market conditions.
Limited Growth History (-9.39% CAGR)
Observation: Below-average 5-year sales growth trajectory.
Analysis: Low sales CAGR may indicate mature markets or limited growth opportunities.
Elevated Debt Levels (D/E: 1.02)
Observation: High leverage increases financial risk and interest burden.
Analysis: High debt-to-equity ratios require monitoring of debt servicing capability.
Weak Interest Coverage (-1.96x)
Observation: Limited ability to service debt obligations from earnings.
Analysis: Low interest coverage raises concerns about financial stability.
Limited Institutional Interest (FII+DII: 0.11%)
Observation: Low institutional participation may affect liquidity.
Analysis: Limited institutional interest may indicate size constraints or visibility issues.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
Mangalam Drugs and Organics Ltd vs Pharmaceuticals Peers
Peer Comparison - Pharmaceuticals
Compare Mangalam Drugs and Organics Ltd with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
Mangalam Drugs and Organics LtdMangalam Drugs ...Selected✓ MANGALAM • 532637 | 0/100 | ₹26.98₹27 | ₹43.97₹43.97 | — — | -34.77%Poor -34.77% Poor | -14.01%Poor -14.01% Poor | 1.02Average 1.0 Average | — — | -9.39%Poor -9.39% Poor | 0.00% |
Sun Pharmaceutical Industries LtdSun Pharmaceuti... SUNPHARMA • 524715 | 66.4/100 | ₹1990.50₹1991 | ₹468821.49₹468821.49 | 37.73Average 37.7 Average | 15.95%Good 15.95% Good | 20.53%Excellent 20.53% Excellent | 0.06Excellent 0.1 Excellent | 16.75%Excellent 16.75% Excellent | 11.78%Good 11.78% Good | 0.82% |
Divis Laboratories LtdDivis Laborator... DIVISLAB • 532488 | 56.3/100 | ₹8056.00₹8056 | ₹193163.97₹193163.97 | 73.64Average 73.6 Average | 16.53%Good 16.53% Good | 21.96%Excellent 21.96% Excellent | 0.00Excellent 0.0 Excellent | 5.71%Good 5.71% Good | 8.67%Good 8.67% Good | 0.41% |
Torrent Pharmaceuticals LtdTorrent Pharmac... TORNTPHARM • 500420 | 51.4/100 | ₹5122.80₹5123 | ₹169902.02₹169902.02 | 77.52Average 77.5 Average | 27.43%Excellent 27.43% Excellent | 15.19%Good 15.19% Good | 1.79Average 1.8 Average | 12.07%Good 12.07% Good | 11.80%Good 11.80% Good | 0.76% |
Cipla LtdCipla Ltd... CIPLA • 500087 | 40.2/100 | ₹1473.20₹1473 | ₹116131.81₹116131.81 | 30.51Average 30.5 Average | 11.60%Average 11.60% Average | 15.49%Good 15.49% Good | 0.02Excellent 0.0 Excellent | 9.94%Good 9.94% Good | 8.01%Good 8.01% Good | 0.90% |
Zydus Lifesciences LtdZydus Lifescien... ZYDUSLIFE • 532321 | 74.1/100 | ₹1078.30₹1078 | ₹115375.77₹115375.77 | 21.26Average 21.3 Average | 21.25%Excellent 21.25% Excellent | 21.14%Excellent 21.14% Excellent | 0.46Excellent 0.5 Excellent | 18.77%Excellent 18.77% Excellent | 12.45%Good 12.45% Good | 0.09% |
Lupin LtdLupin Ltd... LUPIN • 500257 | 83.4/100 | ₹2415.00₹2415 | ₹113976.53₹113976.53 | 20.04Average 20.0 Average | 28.68%Excellent 28.68% Excellent | 29.93%Excellent 29.93% Excellent | 0.29Excellent 0.3 Excellent | 37.02%Excellent 37.02% Excellent | 13.02%Good 13.02% Good | 0.72% |
Mankind Pharma LtdMankind Pharma ... MANKIND • 543904 | 61.5/100 | ₹2469.60₹2470 | ₹105053.91₹105053.91 | 52.29Average 52.3 Average | 13.12%Average 13.12% Average | 13.50%Average 13.50% Average | 0.39Excellent 0.4 Excellent | 10.52%Good 10.52% Good | 18.10%Excellent 18.10% Excellent | 0.04% |
Dr Reddys Laboratories LtdDr Reddys Labor... DRREDDY • 500124 | 41/100 | ₹1148.10₹1148 | ₹102660.46₹102660.46 | 25.62Average 25.6 Average | 11.22%Average 11.22% Average | 13.04%Average 13.04% Average | 0.20Excellent 0.2 Excellent | 15.44%Excellent 15.44% Excellent | 12.09%Good 12.09% Good | 0.65% |
Aurobindo Pharma LtdAurobindo Pharm... AUROPHARMA • 524804 | 24.6/100 | ₹1580.20₹1580 | ₹90035.87₹90035.87 | 25.38Average 25.4 Average | 10.06%Average 10.06% Average | 12.80%Average 12.80% Average | 0.21Excellent 0.2 Excellent | 0.80%Average 0.80% Average | 6.32%Good 6.32% Good | 0.26% |
Laurus Labs LtdLaurus Labs Ltd... LAURUSLABS • 540222 | 34.1/100 | ₹1816.20₹1816 | ₹84016.75₹84016.75 | 93.94Average 93.9 Average | 18.30%Good 18.30% Good | 17.76%Good 17.76% Good | 0.48Excellent 0.5 Excellent | -1.89%Poor -1.89% Poor | 7.19%Good 7.19% Good | 0.13% |
Top Pharmaceuticals Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Sun Pharmaceutical Industries Ltd share price468821.49 Cr
- Divis Laboratories Ltd share price193163.97 Cr
- Torrent Pharmaceuticals Ltd share price169902.02 Cr
- Cipla Ltd share price116131.81 Cr
- Zydus Lifesciences Ltd share price115375.77 Cr
Mangalam Drugs and Organics Ltd PE Ratio History
Historical price-to-earnings ratio for MANGALAM — last 5 years
| Year | EPS (₹) | Price (₹) | P/E Ratio |
|---|---|---|---|
| FY 2025 | ₹4.25 | ₹27.51 | 6.5x |
| FY 2023 | ₹0.80 | ₹98.15 | 122.7x |
| FY 2022 | ₹12.42 | ₹137.15 | 11x |
P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.
Mangalam Drugs and Organics Ltd Quarterly Performance
Latest quarterly metrics for MANGALAM — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
-7.54%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
-8806.67%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
-9.39%
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
N/A
Compounded annual net profit growth over 5 years
Mangalam Drugs and Organics Ltd Technical Indicators
SMA 50, SMA 200, RSI and volume signals for MANGALAM — calculated from daily price history
Momentum is balanced — neither overbought nor oversold.
Technical indicators are for educational purposes only. Not investment advice.
Mangalam Drugs and Organics Ltd Financial Statements
Annual income statement, balance sheet and cash flow for Mangalam Drugs and Organics Ltd (MANGALAM) — sourced from NSE/BSE filings.
Loading Financial Statements...
Fetching financial data for Mangalam Drugs and Organics Ltd
About MANGALAM (Mangalam Drugs and Organics Ltd)
Mangalam Drugs and Organics Ltd is a prominent player in the Indian pharmaceutical landscape, focusing on the intricate world of active pharmaceutical ingredients (APIs) and crucia...l chemical intermediates. With a steadfast commitment to quality and innovation, Mangalam manufactures a diverse portfolio of essential pharmaceutical components. The company serves as a vital link in the pharmaceutical supply chain, enabling the production of various life-saving medications. Their facilities are designed to meet stringent international regulatory standards, ensuring the efficacy and safety of their products. Mangalam actively contributes to the healthcare sector by providing reliable and affordable API solutions. Mangalam's extensive product range encompasses a spectrum of therapeutic categories, addressing widespread health concerns. They specialize in manufacturing APIs for antiviral medications, antimalarial drugs, and cardiovascular treatments, as well as providing essential ingredients for pain management and urinary tract infections. The company carefully manages its manufacturing processes, adhering to sustainable practices and reducing environmental impact. Mangalam is dedicated to research and development, constantly seeking to improve existing products and develop new, innovative API solutions to address emerging healthcare needs. The company's focus on continuous improvement and commitment to excellence has solidified its position as a trusted supplier. Beyond manufacturing, Mangalam Drugs and Organics actively fosters collaborations with pharmaceutical companies and research institutions. This collaborative approach strengthens their capabilities and facilitates the development of cutting-edge pharmaceutical solutions. With a strong focus on customer satisfaction and technical support, Mangalam strives to build long-term partnerships with its clients. The company is committed to upholding ethical business practices and maintaining transparency in its operations. Mangalam aims to improve access to affordable and high-quality medicines by providing crucial pharmaceutical ingredients. Their efforts contribute to a healthier future for communities.
Company Details
Key Leadership
Corporate Events
Latest News
MANGALAM Share Price: Frequently Asked Questions
What is the current share price of Mangalam Drugs and Organics Ltd?
Mangalam Drugs and Organics Ltd (MANGALAM) trades at ₹26.98 on NSE and BSE. Market cap ₹43.97 (Cr). Educational data only.
What is the P/E ratio of Mangalam Drugs and Organics Ltd?
Mangalam Drugs and Organics Ltd has a P/E of N/Ax vs industry average 34.89x.
What is the Bull Run score for Mangalam Drugs and Organics Ltd?
Mangalam Drugs and Organics Ltd has a Bull Run score of 0/100 based on 25+ financial parameters.
Does Mangalam Drugs and Organics Ltd pay dividends?
Mangalam Drugs and Organics Ltd has a dividend yield of 0.00%. Past dividends don't guarantee future payments.
What is the ROE of Mangalam Drugs and Organics Ltd?
Mangalam Drugs and Organics Ltd has ROE of -34.77%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Mangalam Drugs and Organics Ltd?
Mangalam Drugs and Organics Ltd has debt-to-equity of 1.02.
Is Mangalam Drugs and Organics Ltd a good investment?
Bull Run gives Mangalam Drugs and Organics Ltd a score of 0/100. This is not investment advice — consult a SEBI-registered advisor.